GlassScriptPhysician profile
Jenna C Mock
NPI 1164787370
$5,000.55
in general payments reported to CMS, 2019-2025
20 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,375 · 2022: $1,113 · 2023: $929 · 2024: $572 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395 · Travel and Lodging: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.15 |
| Travel and Lodging | $117.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,871.29 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,046.41 | 2021-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $590.65 | 2021-2022 | |
| Medtronic, INC. | $240.03 | 2022-2025 | Symplicity G3 |
| Janssen Pharmaceuticals, INC | $231.18 | 2021 | |
| Abbott Laboratories | $152.08 | 2021-2023 | Mitraclip |
| Esperion Therapeutics, INC. | $135.16 | 2021-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $133.64 | 2021-2023 | Andexxa |
| Novartis Pharmaceuticals Corporation | $118.15 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.93 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $76.42 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $57.76 | 2021-2024 | Winrevair |
| E.R. Squibb & Sons, L.L.C. | $44.88 | 2022-2025 | Eliquis |
| Boston Scientific Corporation | $42.08 | 2022-2023 | |
| Atricure, INC. | $42.01 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $32.97 | 2025 | |
| Pfizer INC. | $24.89 | 2021 | |
| Novo Nordisk INC | $20.75 | 2023 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $17.61 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Mock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.